French firm Mauna Kea Technologies, inventor of Cellvizio- the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, and China-based Tasly Pharmaceutical Group have announced the achievement of a new key milestone in their strategic partnership.
Cellvizio technology uniquely delivers in vivo cellular visualisation which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions.
Tasly Mauna Kea Medical Engineering Technology Co., based in the Zheijang province of China, is now legally incorporated with registered capital of RMB 250 million (EUR 35 million).
The joint venture (JV) will serve as the exclusive commercial platform for expanding the reach of Cellvizio into the Chinese domestic market and will launch a dedicated platform for neurosurgical applications worldwide.
